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Abstract

Since the mid-l 960's, all infants in the US have received intramuscular vitamin K
(IMVK) as a prophylactic measure against hemorrhagic disease of the newborn (HDN). Because
the human race has obviously survived for so many years without this medical intervention, there
is some question concerning the universal necessity of this practice.
Infants are born with comparatively low levels of vitamin K, a compound vital for the
carboxylation of serum clotting factors. In the absence of adequately carboxylated clotting
proteins, infants are at risk for developing HDN. This condition can cause severe complications,
including mental retardation and death. IMVK significantly reduces incidence of the disease.
Though very few infants will develop this condition, supplementation remains universal.
There is some controversy to this practice. One British study showed a possible
connection between IMVK and childhood cancer. These results have never been duplicated.
Other points of controversy include the invasive nature of the procedure and the incurred cost,
particularly where so few infants require prophylaxis.
There are no good criteria for establishing which infants are at risk for HDN. Therefore
the conclusion is, as it has been proven safe and the most effective means by which to eradicate
HDN, intramuscular vitamin K is a reasonable prophylactic measure in the infant.

Introduction

Adaptation to the environment in which man finds himself is one hallmark of human
existence. From gradual evolutionary changes such as skin pigmentation for optimal vitamin D
and folate to acute changes such as prevalence of absorption proteins in a dietary nutrient
insufficiency, the human body masterfully adapts to ensure essential nutrient adequacy. In
almost any environment, it will adjust and adapt to survive on the resources and elements
available. In spite of this innate ability, modem man has found various synthetic, external
methods to compensate for supposed biologic flaws. In fact, with all of the modem medical
interventions in human health, one might think it impossible to live without these many and great
developments. But the reality is, man has survived for thousands of years without these
interventions.
One example of this phenomenon is Vitamin K. According to biochemical studies on
infant serum, Vitamin K levels are deficient among this population (1). Furthermore, human
breast milk is not a good source of this vitamin and infants do not yet have the intestinal flora to
produce vitamin K (1-2). Hemorrhagic disease of the newborn, a bleeding disorder seen in some
infants, is attributed to deficiency of this vitamin. To prevent this disease, all infants in the
United States are given intramuscular vitamin K immediately after birth. This supplementation
has only been standard practice for the past 30-40 years (3). One might wonder, if vitamin K is
such a problem as to warrant across the board supplementation, how have humans survived
infancy to populate the earth so plentifully without this medical intervention? Furthermore, if
serum levels of vitamin K truly are inadequate in the infant, it would seem that our adaptive
abilities have failed us. This paper seeks to address this inconsistency and it will review the
literature regarding these questions. It will describe the disease, hemorrhagic disease of the

newborn (HDN), discuss vitamin K's role in disease pathogenesis, the reasoning behind the
supplementation, and the different viewpoints for and against the supplementation.

Hemorrhagic Disease of the Newborn
Hemorrhagic disease of the newborn is a disorder experienced by some infants due to an
insufficiency of vitamin K dependent blood clotting factors. It is characterized by bleeding, most
commonly in the mucus membranes, skin, umbilicus, retroperitonium, urinary tract, and
gastrointestinal tract ( 1). In the more serious cases the infant will experience intracranial
hemorrhage, resulting in severe mental handicap or death (1 ). Highest occurrence of the disease
is seen in males, infants of the oriental race, and among babies born in the early summer (2-3).
Furthermore, it is almost exclusively found in breast-fed infants (2). As nature's baby food,
breast milk is a nearly perfect formulation of nutrients for the infant. It is, however, a poor
source of vitamin K, providing only 15 mcg/L (4). Newborn infants do not yet have the gut flora
to synthesize the bacteria in the colon and therefore must rely solely on exogenous sources.
Infants with liver disease or malabsorption disorders are also prone to this disease independent of
any other factor. This is due to either an inability to synthesize the vitamin K dependent clotting
factors in the liver or an inability to absorb vitamin Kin the gut (2).
There are three different stages ofHDN: early, classic and late. Early HDN will occur
within the first 24 to 48 hours of life. It is principally the result of maternal use of anticonvulsant
drugs, antibiotics (cephalosporins ), anti-tuberculosis agents, and warfarin. These drugs induce a
state of vitamin deficiency in the mother that is then transferred to the infant, for whom the
deficiency is extremely harmful, particularly because the infant has very little amounts of this

vitamin to begin with. Incidence among the high risk groups (including maternal use of the
above listed drugs and absence of prophylactic vitamin Kat birth) is less than 5% (1-2).
Classic HDN is seen with in the first week of life. Risk factors include late onset of
feeding or poor intake in the first days of life, marginal content of vitamin K in the breast milk,
and absence of vitamin K prophylaxis at birth (1,5). Incidence of the disease among infants who
have not received the prophylactic measures is 0.01-1.5% (1).
Late HON occurs between weeks 2-12 of life. Risk factors for this condition include
marginal intake of vitamin K among breast-fed infants, malabsorption of vitamin K, liver
disease, and the use of oral vitamin K prophylaxis rather than intramuscular prophylaxis (1,5).
Approximately 43% of cases are associated with liver disease (5). Infants who develop late
HDN will often exhibit warning signs, including jaundice, pale stools, failure to thrive, mild
bruising, and umbilical oozing (1). Incidence of this disease among infants not receiving
prophylactic vitamin K is 4-10 per
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vital role in the blood-clotting cascade. In the relative absence of vitamin K, these proteins
remain only partially carboxylated and therefore have a low affinity for binding with calcium.
When these compounds are fully carboxylated, in the presence of vitamin K, their ability to bind
to calcium increases ten-fold above the partially carboxylated protein. The ability of the clotting
factors to bind to calcium is essential for it to function in its role in clot formation (6). Thus, in
the absence of vitamin K, serum levels of clotting factors are low and hemorrhage ensues, as in
HDN.

Vitamin K in the Infant

The two biologically active forms of vitamin Kare phyloquinone (Kl) and menaquinone
(K2). In infants, serum levels of Kl are markedly lower than adult levels and K2 is non-existent
(5). This is attributed to poor placental transfer of vitamin K to the fetus (5,7). Of course the
child has adequate clotting factors in utero from the mother. But because storage levels of the
vitamin are so low, the infant must rely on dietary sources immediately after birth to maintain
adequate amounts of clotting factors. Infants who are formula fed receive large amounts of
vitamin K in their food source, and therefore HON is rarely seen among this group of infants.
However, as already stated, breast milk is a poor source of this vitamin. Furthermore, the halflife of vitamin Kin the blood is only 24 hours, so whatever amounts the infant receives does not
stay long. Yet another strike against breast-fed infants is that they take longer to develop vitamin
K producing bacteria in the gut, particularly when compared to infants fed cow's milk (5). These
facts form the premise for the idea that infants are deficient in the vitamin. The fact remains,
however, that only a fraction of infants born actually develop coagulation abnormalities, even
without prophylactic vitamin K ( 1).

Vitamin K dependent clotting factors are present in much smaller quantities in the infant
compared to the adult. Serum levels are only 30-60% of normal adult levels, even in infants who
received intramuscular vitamin K at birth. This "deficiency" is not severe enough to cause
symptoms (5,7). Some animal based studies have indicated that the low clotting factors could be
a result of inadequate mRNA specific for the production of various clotting factors (5). Rather
than boosting clotting factor levels, some evidence suggests that the real value in intramuscular
prophylaxis is in its ability to prevent a fall in clotting factor concentration, a direct result of
worsening vitamin K status within the first five days of life to which some infants may be prone
(5). It would seem, then, that infants are not deficient in the vitamin, but have a lower need
secondary to lower synthesis. Only that fraction of infants who, for one reason or another,
experience a drastic drop in serum vitamin K levels really require this currently universal
prophylactic measure.

Prophylactic Supplementation

In order to prevent the occurrence of HDN, the American Academy of Pediatrics issued a
policy in 1961 stating that all infants should receive intramuscular vitamin Kat birth (3,5). Since
that time the United States has universally administered vitamin K in the newborn population, a
practice which has shown to effectively reduce the disease incidence (5). Current
supplementation practice is administration of 1 mg (5).
There is some criticism for this practice of universal vitamin K supplementation. For
example, in 1991 a well-designed study published in the British Journal of Medicine reported
that prophylactic vitamin K increased the incidence of childhood cancer (8). In their prospective
study they found a relationship between intramuscular vitamin Kand childhood cancer with an

odds ration of 2.0 with 95% confidence. In their analysis, if, in a group of 100,000 infants, no
infant received intramuscular vitamin K at birth there would be 980 cases of childhood leukemia.
If all children were given intramuscular vitamin K at birth, there would be 1960 cases of
childhood cancer. On the converse, if no child received intramuscular vitamin K, there would be
30-60 cases of late HDN whereas if all children received intramuscular vitamin K there would be
1 case of late HDN. As a result of their findings, they hypothesized that the relative deficiency
of this vitamin at birth is an evolutionary protective effect against mutagenesis in the neonate (8).
As a result of this publication, hospitals in the United Kingdom and other countries across
Europe stopped using intramuscular vitamin K at birth. They subsequently saw a rise in disease
incidence, as was predicted. This issue remains a controversial topic, particularly because no
study since has been able to repeat these results, most showing no significant connection
whatsoever (9). In the United States vitamin K is considered a safe prophylactic measure (5).
Many European countries, however, still do not use intramuscular vitamin K.
Another source of criticism for universal vitamin K prophylaxis is the excessive cost,
particularly when few infants truly need the dose. It is estimated that each dose of 1 mg costs $1
(3). This cost will certainly accumulate rapidly with the many births each day across the nation.
However, when taken into comparison with the costs of treating affected individuals, particularly
those who experience lifelong complications as a result, it truly is cost effective, even in light of
the low incidence of the disease. Apart from the medical cost, the emotional pain that is saved
for those families who may be affected is certainly worth the monetary expense.
As a result of this criticism to intramuscular vitamin K, especially due to its implication
in causing childhood cancer, some attempts have been made to find alternative, effective
prophylactic measures. In Europe, for example, many countries have begun oral

supplementation of vitamin K, a practice which is not linked to cancer, is less invasive, and is
cheaper (1,3,5). Oral vitamin K has not been found to be as effective as intramuscular vitamin K
at reducing HDN incidence. Whereas intramuscular vitamin K essentially eradicated incidence
of the disease, cases of the disease still arise with oral supplementation. Due to the intestinal
barrier and its role in absorption regulation, oral vitamin K does not increase body stores to the
same extent as intramuscular vitamin Kand therefore more than one dose is needed over the
course of a month. Furthermore, compliance with the treatment decreases with oral
supplementation because subsequent doses after the initial dose at birth must be administered at
home. Parents too often forget or lose the dose and the supplementation never happens (5).
Other factors that decrease the effectiveness of oral supplementation include poor absorption
from the gut and the short duration of the effective dose (1).
Another alternative has been maternal supplementation, both during pregnancy and
during lactation. Transport of vitamin K across the placenta to the fetus is poor but not
completely absent and therefore maternal supplementation may be effective at increasing
newborn blood supply (5). This would not likely protect against late HDN. Supplementation
during lactation of 2.5 mg/d may increase breast-milk content to approximately 26 ng/ml,
meeting the recommended levels for formula milk ( 10). This may be an effective prophylaxis,
but it is not widely recognized or used. Again, the major problem with either of these practices
is the inevitable low level of compliance.
Because HDN is a problem for only a small number of infants, some hospitals began
selectively supplementing infants with vitamin K. Infants were selected as high risk infants if
they were premature, were low birth weight, experienced a traumatic delivery, had delayed or
inadequate intake, were on antibiotics, had evidence of bleeding or bruising, or required early

surgery. This resulted in an increase in HDN incidence where, before, it had been essentially
eradicated. The problem was, most infants who developed HDN were previously healthy and
therefore considered low risk. There are no good criteria to effectively distinguish a high risk
infant from a low risk infant and therefore, the practice of supplementation once again became
universal to all infants (1 ).

Conclusion

When looking at the surface of the issue, one might conclude that either biology has
failed the human race in nutrient adaptation, or there is a tremendous amount of unnecessary
supplementation occurring. Upon closer examination, however, it is apparent that biology
indeed has not failed us at all. It is normal to have defects and complications of one kind or
another in normal metabolic processes in a small percentage of the population. As in the case of
HND, when there exists such a simple measure to prevent occurrence of these defects, it is
certainly appropriate to practice this measure. Furthermore, where there are no accurate and
reliable tests to separate at risk populations from others, it is certainly appropriate to initiate this
preventative measure across the board. In spite of the incurred cost or pain or invasiveness of
this practice, it must be less than the medical expenses and pain incurred by affected children and
the ensuing defects and complications they experience. As it is generally accepted to be both
safe and effective, vitamin K prophylaxis for all infants is a logical and necessary medical
treatment.
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